Why Use Intra-Tumoral Immunotherapy with Immuno-Modulator Compounds

1
Why Use Intra-Tumoral Immunotherapy with
Immuno-Modulator Compounds?
2

• Intra-tumoral Immunotherapy, consists of a unique
  blend of cancer fighting medicines and
  immuno-modulating compounds for the treatment of
  solid tumor cancers.

3

• Each Intra-tumoral Immunotherapy compound plays a
  vital role in cancer therapy. Intra-tumoral
  Immunotherapy is water-soluble and administered
  by way of high pressure injection, placing cancer
  medicines into the tumor and corresponding tumor
  cells.

4

• A newly discovered oxidant hardens the tumor mass
  by disturbing existing blood vessels within the
  tumor, ultimately leading to higher concentration
  of injected cancer medicines. This hardening of
  tumor cells, effectively changes the
  extracellular matrix by altering its
  morphological and biochemical components, e.g.,
  collagen, elastic fibers, reticular fibers,
  fibronectin, proteoglycans, hyaluronic acid and
  other large molecules, eventually morphing into
  a soft, semi-solid state within the tumor.

5

• Another unique feature of Intra-tumoral
  Immunotherapy is its ability to avoid
  administering standard conventional cancer
  treatment protocols (e.g. Surgery, radiation
  and/or chemotherapy) in exchange for a
  minimally-invasive procedure with no side
  effects, and to benefit from newer
  immuno-modulator compounds. When multiple
  autologous tumor antigens are released from the
  coagulated tumor, cell death can become a
  "priming" event for T cell response, which then
  induces potent immunity within the patient's
  entire body.

6

• These cell deaths are called a "good death",
  which elicit a weak immune response as an in-vivo
  self-vaccination promoted by an immunologic
  modulator, i.e., a small molecule haptens. The
  immuno-modulator reacts within the denatured
  tumor, causing modified cell debris or matrixes
  with tumor antigens to produce new and more
  immuno reactive antigens for better stimulating
  the host immune system. Therefore, the role of
  the immuno-modulator is important in enhancing
  the immunological response to tumor-associated
  antigens.

7
Clinical Immuno-therapy Pearls

• William B. Coley, MD injected live and
  inactivated Streptococcus pyogenes and Serratia
  marcescens into patients tumors in 1891 to try
  to harness the immune system in the treatment of
  cancer.
• Lack of a known MOA for Coleys toxins and the
  risks of infecting cancer patients with
  pathogenic bacteria caused oncologists to adopt
  surgery and radiotherapy as standard treatments.

8

• In the 1970s, large doses of IL-2 were shown to
  be effective when administered to patients with
  established, metastatic cancers by enhancing
  T-cell production.
• The first monoclonal antibody approved by the FDA
  for the treatment of a cancer, non-Hodgkins
  lymphoma, came in 1997.

9

• In 2010, the FDA approved the first cancer
  vaccine, sipuleucel-T, for castration-resistant
  prostate cancer.
• In 2011, Ipilimumab, an antibody targeting CTLA-4
  was approved by the FDA for use in patients with
  melanoma.

10

• In 2014, in Japan nivolumab became the first PD-1
  inhibitor to achieve regulatory approval in
  melanoma.
• Promising results have also been posted for the
  experimental anti-PD-L1 antibody MPDL3280A in
  melanoma, lung cancer, and bladder cancer.11,12

11
Intra-tumoral Immunotherapy Tumor Targeted
Immuno-Therapy
12

• Monoclonal Antibody Cancer Therapy
• Tumor-targeted Immuno-Modulating Cancer Therapy
  (learn more )
• Integrative, Alternative and Complementary
  Medicine

13

• Cord Blood Stem Cell Restoration (overall immune
  and targeted organ restoration)
• Advanced Cancer Diagnostics (with 24 hr. CT, MRI,
  and PET Imaging).
• Conventional Standard of Practice Therapy (when
  indicated)

14

• To know more information, visit us

http//www.livercancercentersofamerica.com/